|
Product class:
|
Authorized package
|
|
Medicinal product class:
|
Veterinary medicine
|
|
Package code:
|
1259973
|
|
Name of medicinal product:
|
Virbagen Omega
|
|
Active substances:
|
|
|
ATC code:
|
QL03AB90
|
|
Dosage form:
|
lyophilisate and solvent for suspension for injection
|
|
Route of administration:
|
intravenous use; subcutaneous use
|
|
Strengh:
|
10000000ühik
|
|
Amount in package:
|
5TK
|
|
Legal status for supply*:
|
Subject to medicinal prescription
|
|
Class of active substance:
|
|
|
Additional information:
|
lahusti 1 ml
|
|
Indication:
|
Dogs :
Reduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age.
Cats :
Treatment of cats infected with FeLV and/or FIV, in non-terminal clinical stages, from the age of 9 weeks. In a field study conducted, it was observed that there was :
- a reduction of clinical signs during the symptomatic phase (4 months)
- a reduction of mortality :
• in anaemic cats, mortality rate of about 60% at 4, 6, 9 and 12 months was reduced by approximately 30% following treatment with interferon.
• in non-anaemic cats, mortality rate of 50 % in cats infected by FeLV was reduced by 20% following treatment with interferon. In cats infected by FIV, mortality was low (5%) and was not influenced by the treatment.
|
|
Safety features:
|
No
|
|
Summary of product characteristics (SPC):
|
|
|
Package information leaflet (PIL):
|
EST
|
|
Labelling:
|
|
|
Withdrawal time:
|
Ei rakendata.
|
|
Species:
|
koer, kass
|
|
Last imported to Estonia:
|
Never imported to Estonia
|
|
Marketing authorization holder:
|
Virbac
|
|
Marketing authorization number:
|
EU/2/01/030
|
|
Marketing authorization issued on:
|
November 6, 2001
|
|
Marketing authorization expires on:
|
Unlimited
|
|
Marketing authorization procedure type:
|
Centralised
|
Entry/Changing date:
November 23, 2011
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription
You can download Acrobat Reader fromhere